Jpmorgan Chase & CO Sarepta Therapeutics, Inc. Transaction History
Jpmorgan Chase & CO
- $1.27 Trillion
- Q1 2025
A detailed history of Jpmorgan Chase & CO transactions in Sarepta Therapeutics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 2,244,432 shares of SRPT stock, worth $41 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
2,244,432
Previous 2,020,604
11.08%
Holding current value
$41 Million
Previous $246 Million
41.7%
% of portfolio
0.01%
Previous 0.02%
Shares
20 transactions
Others Institutions Holding SRPT
# of Institutions
468Shares Held
85.8MCall Options Held
5.14MPut Options Held
3.86M-
Black Rock Inc. New York, NY10.3MShares$189 Million0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.16MShares$167 Million0.0% of portfolio
-
State Street Corp Boston, MA4.7MShares$85.8 Million0.0% of portfolio
-
D. E. Shaw & Co., Inc. New York, NY4.48MShares$81.8 Million0.06% of portfolio
-
Wellington Management Group LLP Boston, MA2.53MShares$46.2 Million0.01% of portfolio
About Sarepta Therapeutics, Inc.
- Ticker SRPT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 87,567,904
- Market Cap $1.6B
- Description
- Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...